AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, once a week for 1 cycle.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purdue Pegboard
Description: This test consists of a series of timed hand coordination and dexterity tasks.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, once a week for 2 cycles.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Test of Attention
Description: A cognitive test assessing focus and attention.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-minute Walk
Description: This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 851B
Description: 851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, once a week for 1 cycle.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, twice a week for 1 cycle.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, once a week for 2 cycles.
Study NCT00312286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 851B
Description: 851B placebo-matching gel, topically, twice a week for 2 cycles.
Study NCT02456129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
Study NCT02456129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] Vilaprisan
Description: an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
Study NCT02456129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Itraconazole(ITZ)
Description: Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
Study NCT04958603 — intervention group
Intervention type: PROCEDURE
Intervention: L type release surgery
Description: Lateral release of the lateral support belt
Study NCT00189137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide and doxorubicin vs gemcitabine and docetaxel
Description: Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection.
Study NCT00189137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide and doxorubicin vs gemcitabine and docetaxel
Description: Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection.
Study NCT01238887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose placebo pill
Description: Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
Study NCT01238887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)
Description: The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
Study NCT01238887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia Cambogia derived Hydroxycitric Acid
Description: The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
Study NCT04281667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotics
Description: Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
Study NCT04281667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
Study NCT04281667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Preparation
Description: Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
Study NCT04281667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechanical Bowel Preparation
Description: Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
Study NCT00832013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: See detailed description
Study NCT00688168 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires measuring pain and other symptoms, mood, and quality of life.
Study NCT01018602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: 100 mg per day over 24 months
Study NCT01018602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inactive pill
Description: 1 pill per day over 24 months
Study NCT03410654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus, Extended Release, (Envarsus Xr)
Description: After conversion of tacrolimus immediate release to tacrolimus extended release.
Study NCT00949975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9668
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Study NCT00949975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9668
Description: 2 x 10 mg oral tablets twice daily (bid) for 12 weeks
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Grip Dynamometer
Description: This tests measures hand grip strength.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Description: This test is used to assess cognitive abilities.
Study NCT04023019 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nuwiq
Description: Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study NCT00949975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9668
Description: 2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
Study NCT00949975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD9668 Placebo
Description: 2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Performance Function
Description: This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
Study NCT00309088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT00309088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT02534350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presatovir
Description: Tablets administered orally or via nasogastric (NG) tube once daily
Study NCT02534350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally or via NG tube once daily
Study NCT04023019 — intervention group
Intervention type: BIOLOGICAL
Intervention: Octanate
Description: Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study NCT00688168 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurocognitive Testing
Description: A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
Study NCT00688168 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurosensory Testing
Description: Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
Study NCT03383718 — intervention group
Intervention type: PROCEDURE
Intervention: Revascularisation
Description: Percutaneous coronary intervention or coronary artery bypass surgery
Study NCT03383718 — intervention group
Intervention type: OTHER
Intervention: Optimal Medical Treatment/OMT
Description: Standard of care in stable coronary artery disease or after acute myocardial infarction.
Study NCT00738543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHOLE GROUP OF 48 VOLUNTEERS
Description: Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
Study NCT03302793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.
Study NCT02578108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve diagnostic block with lidocaine (local anesthetic)
Description: sensory denervation of the knee joint
Study NCT04023019 — intervention group
Intervention type: BIOLOGICAL
Intervention: Wilate
Description: Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study NCT04023019 — intervention group
Intervention type: BIOLOGICAL
Intervention: Emicizumab
Description: Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomechanical Assessments of Dysmetria
Description: Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurophysiological assessment of brain activity
Description: Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
Study NCT02488031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomechanical gait analysis
Description: Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
Study NCT04023019 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant factor VIIa (rFVIIa)
Description: Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study NCT04023019 — intervention group
Intervention type: BIOLOGICAL
Intervention: Activated prothrombin complex concentrate (aPCC)
Description: Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study NCT02578108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve radiofrequency ablation
Description: Ablation of the genicular nerves of the knee by radiofrequency energy
Study NCT04094155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: retinal vascular analysis
Description: Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
Study NCT00549536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)
Description: 1500 mg of elemental calcium per day.
Study NCT00549536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)
Description: 1500 mg of elemental calcium per day.
Study NCT01184235 — intervention group
Intervention type: DRUG
Intervention: Pharmacological Intervention
Description: This study will include those anticipating or receiving any pharmacological intervention
Study NCT02441218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: 2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
Study NCT03302793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied for 20 minutes.
Study NCT03302793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS sham
Study NCT04593940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: study drug or matching placebo
Study NCT04593940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: study drug or matching placebo
Study NCT04593940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Standard of Care
Study NCT04593940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenicriviroc (closed to enrollment as of 3-Sep-2021)
Description: study drug or matching placebo
Study NCT02441218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
Study NCT01297855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Colistimethate Sodium dose 2.5-5mg/kg/day
Study NCT01297855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin plus Rifampicin
Description: Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
Study NCT03537339 — intervention group
Intervention type: OTHER
Intervention: Record general information
Description: Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
Study NCT03047863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repair Control EGF®
Description: A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)
Study NCT03047863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream without rhEGF
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Study NCT03648281 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study NCT04158713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine
Description: Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
Study NCT04158713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine
Description: Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
Study NCT03754569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal biopsies after complete macroscopic cytoreduction
Description: We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
Study NCT06253286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clear aligner treatment for orthodontics patients
Description: patient are instructed to wear aligners
Study NCT01507584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENSIMED Triggerfish
Description: Comparison of fluctuation of Intraocular pressures with different class of drugs
Study NCT02600325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir 100mg/50mg
Description: Grazoprevir/Elbasvir 100mg/50mg
Study NCT01426425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freezor Xtra Cryoablation Catheter
Description: Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
Study NCT01264250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2927
Description: Single dose of AZD2927
Study NCT01264250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study NCT01754220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast is a leukotriene receptor antagonist
Study NCT02023164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 Injection
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study NCT02023164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes